STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.

Related Keywords

United States ,America ,Insitute Mikhail Kosiborod ,Campbellp Semaglutide ,Mikhail Kosiborod ,Saint Luke Mid America Heart Institute ,Saint Luke Health System ,American College Of Cardiology ,Saint Luke ,Mid America Heart Insitute ,American College ,Annual Scientific Sessions ,Mid America Heart Institute ,Kansas City ,Kansas City Cardiomyopathy Questionnaire ,